TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04212559

Intervention type: OTHER
Intervention: Received negative pressure ventilation
Description: Patients who received a negative pressure during inspiratory phase.
Study: NCT04257786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1ry cyto-reductive surgery
Description: 1ry surgery then chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by surgery
Description: chemotherapy then surgery
Study: NCT04132869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports Readiness Intervention
Description: Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
Study: NCT01603849

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
Study: NCT01007721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 67100 ED 25 mg
Description: 2 capsules of BI 671800 ED 25 mg
Study: NCT00326716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir + Ritonavir + Combivir
Description: Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
Study: NCT00723762

Intervention type: PROCEDURE
Intervention: Specimen collection
Description: A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
Study: NCT00502112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: 4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
Study: NCT04682717

Intervention type: DEVICE
Intervention: perfusion index monitoring for postinduction hypotension
Description: Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to \<30% of baseline or absolute MAP \<60 mmHg. MAP \<55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR \<50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
Study: NCT02362802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator
Study: NCT05125796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1000 mg intravenous paracetamol in 100 mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol
Description: 50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Application of 5 gr of 5% topical lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL intravenous normal saline infusion+ placebo topical pomade application
Study: NCT01007721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 ED placebo
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study: NCT03181100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT01708941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV or SC
Study: NCT04416269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Anti-diabetes Drugs alone
Description: OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal bolus insulin
Description: Basal insulin with glargine or detemir will be used as per the hospital formulary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental insulin
Description: Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin
Description: Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring (CGM)
Description: A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.
Study: NCT04330664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 Inhibitor
Study: NCT03123445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
Study: NCT01965340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic Therapeutic Drug Monitoring for the intervention group
Study: NCT05270616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic surgery
Description: minimally invasive surgery using the Davinci robotic system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uniport surgery
Description: VATS minimally invasive surgery under the uniportal status
Study: NCT03972306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Administered by subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Administered by subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Administered by subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Administered by Intravenous (IV) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
Study: NCT05270616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiple- port surgery
Description: VATS minimally invasive surgery under the multiple- port status
Study: NCT01455597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
Study: NCT01007721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
Study: NCT02968420

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
Study: NCT03119467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP4010
Description: Escalating doses starting at 25 mg
Study: NCT02810054

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Minimally Invasive Surgical Techniques (MIST)
Description: Using minimally invasive surgical techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgical Techniques (MIST)
Description: Using minimally invasive surgical techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Description: Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
Study: NCT03755830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
Study: NCT03074630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5 weeks 10mg dapagliflozin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 9 weeks 10mg dapagliflozin once daily
Study: NCT01007721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 ED 100 mg
Description: 4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
Study: NCT03961568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: active drug
Study: NCT03315455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
Study: NCT04468659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: IV infusion.
Study: NCT03780881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation confirmation
Description: Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation disconfirmation
Description: Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
Study: NCT01007721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 ED placebo
Description: 4 capsules of BI 671800 ED placebo (bid in the morning and evening)
Study: NCT01681212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study: NCT04468659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion.
Study: NCT04174391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Description: Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
Study: NCT06458868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salt water or tap water before UVA
Description: Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salt water or tap water before UVA
Description: Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
Study: NCT04615104

Intervention type: PROCEDURE
Intervention: Operative
Description: surgical treatment
Study: NCT01480466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity tools in the electronic health record
Description: The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
Study: NCT04615104

Intervention type: PROCEDURE
Intervention: Operative
Description: surgical treatment

Intervention type: PROCEDURE
Intervention: Nonoperative
Description: nonsurgical treatment

Intervention type: PROCEDURE
Intervention: Nonoperative
Description: nonsurgical treatment
Study: NCT02085408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo clinical observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
Study: NCT02030340

Intervention type: PROCEDURE
Intervention: lower urinary tract dysfunction
Description: Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
Study: NCT04454983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipiflow Thermal Pulsation System
Description: The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.